The Affect of FDASIA on Inspections - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Affect of FDASIA on Inspections
David Elder, vice-president, technical at PAREXEL, discusses US legislation allows for inspection of generic-drug activities.

Pharmaceutical Technology
Volume 37, Issue 4, pp. 138


David Elder
Q. How will the new FDASIA user fees affect inspections?

A. On July 9, 2012, President Obama signed into law the Food and Drug Administration Safety and Innovation Act (FDASIA). This legislation passed both the House and Senate with overwhelming bipartisan majorities, signifying an effective, cooperative legislation process that included FDA, Congress, patients, doctors, and the pharmaceutical and medical device industries.

The legislation is intended to provide FDA with added resources and authorities required to bring drugs and devices to market safely and quickly and promote innovation in the biomedical industry. In addition to the reauthorization of the Prescription Drug User Fee Act (PDUFA V) and the Medical Device User Fee and Modernization Act (MDUFMA III), it authorizes user fees for generic drugs and biosimilars. The Act establishes new initiatives, requirements, and authorities in other key areas as well and is certainly worth a careful study by its stakeholders.

The legislation includes explicit provisions relating to inspections but, in addition, it is important to understand the commitments made by FDA during the legislation negotiation time that will also drive implementation. When viewed collectively, I believe that the greatest impact of the new legislation to inspections will be in the area of generic drugs.

The Generic Drug User Fee Act (GDUFA), Title III of FDASIA, authorizes the agency to collect user fees to supplement the agency’s cost for conducting human generic-drug activities. Unlike the legacy user fee acts, GDUFA specifically defines covered FDA activities to include facility inspections. FDA has committed to conducting risk-adjusted biennial CGMP surveillance inspections of generic API and generic finished dosage form (FDF) manufacturers, with the goal of achieving parity of inspection frequency between foreign and domestic firms in FY 2017. One of the specific provisions in GDUFA is the requirement for sites to self-identify, which will provide FDA with a more complete and up-to-date inventory of generic drug establishments.

With a better inventory of generic drug establishments, the ability to allocate user fees to conduct inspections, a mandate to achieve inspection frequency parity among domestic and foreign establishments, a mandate for FDA to annually report year-to-year inspection metrics, and newly defined risk factors that include time since the last inspection, compliance history, and inherent product risk (see FDASIA Section 705), FDA is poised to significantly escalate the number of generic drug inspections worldwide.

This legislation also provides FDA with additional authorities that facilitate and augment its inspection program:

  • Under FDASIA Section 706, drug establishments must provide FDA, upon request, any records FDA would be entitled to obtain during an on-site inspection
  • Under FDASIA Section 707, drugs will be deemed misbranded if a drug establishment delays, denies, or limits an inspection, or refuses to permit entry or inspection
  • Under FDASIA Section 712, FDA may rely upon the inspections of capable foreign government agencies and may protect information received from foreign government agencies from disclosure under the Freedom of Information Act (FDASIA Section 708)
  • Under FDASIA Section 718, there is now extraterritorial jurisdiction over any violation of the law if the drug or other regulated article was intended for import into the United States or if any act in furtherance of the violation was committed in the US.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
29%
Restricts innovation and the development of new drugs.
54%
Has no impact on drug development.
4%
Do not know.
13%
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here